Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 3-(4-((2r)-2-aminopropoxy)phenyl)-n-((1r)-1-(3-fluorophenyl)ethyl)imidazo(1,2-b)pyridazin-6-amine;hexanedioic Acid
1. Ds-6051b
2. 1505515-69-4
3. Taletrectinib Adipate
4. Ds-6051b Adipate
5. 6kll51gnbg
6. Taletrectinib Adipate [usan]
7. 1505515-69-4 (adipate)
8. 3-(4-((r)-2-aminopropoxy)phenyl)-n-((r)-1-(3-fluorophenyl)ethyl)imidazo[1,2-b]pyridazin-6-amine Adipate
9. 3-[4-[((2r)-2-aminopropyl)oxy]phenyl]-n-[(1r)-1-(3-fluorophenyl)ethyl]imidazo[1,2-b]pyridazin-6-amine Monoadipate
10. 3-[4-[(2r)-2-aminopropoxy]phenyl]-n-[(1r)-1-(3-fluorophenyl)ethyl]imidazo[1,2-b]pyridazin-6-amine;hexanedioic Acid
11. Unii-6kll51gnbg
12. Ab-106 Adipate
13. Chembl4650361
14. Schembl16468541
15. Glxc-25968
16. Ex-a4255
17. S8901
18. Ac-36532
19. Hy-131003
20. Cs-0120270
21. F78020
22. 3-(4-((r)-2-aminopropoxy)phenyl)-n-((r)-1-(3-fluorophenyl)ethyl)imidazo[1,2-b]pyridazin-6-amine (1:1)
23. 8-trifluoromethyl-3-cyclopropylmethyl-7-[(4-(2,4-difluorophenyl)-1-piperazinyl)methyl]-1,2,4-triazolo[4,3-a]pyridine
24. Hexanedioic Acid, Compd. With 3-[4-[(2r)-2-aminopropoxy]phenyl]-n-[(1r)-1-(3-fluorophenyl)ethyl]imidazo[1,2-b]pyridazin-6-amine (1:1)
| Molecular Weight | 551.6 g/mol |
|---|---|
| Molecular Formula | C29H34FN5O5 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 12 |
| Exact Mass | 551.25439736 g/mol |
| Monoisotopic Mass | 551.25439736 g/mol |
| Topological Polar Surface Area | 152 Ų |
| Heavy Atom Count | 40 |
| Formal Charge | 0 |
| Complexity | 645 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
NDC Package Code : 72015-007
Start Marketing Date : 2025-06-13
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
NDC Package Code : 72015-007
Start Marketing Date : 2025-06-13
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Taletrectinib is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Lead Product(s): Taletrectinib,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 04, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Taletrectinib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Details : Taletrectinib is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 04, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Ibtrozi (taletrectinib) is an inhibitor of tyrosine kinase ROS1. It is approved for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC.
Lead Product(s): Taletrectinib,Inapplicable
Therapeutic Area: Oncology Brand Name: Ibtrozi
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 11, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Taletrectinib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves IBTROZI™ for Advanced ROS1-Positive Non-Small Cell Lung Cancer
Details : Ibtrozi (taletrectinib) is an inhibitor of tyrosine kinase ROS1. It is approved for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC.
Product Name : Ibtrozi
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 11, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The financing is intended to support the clinical development and commercialization of AB-106 (taletrectinib), in the U.S. Currently, it is being evaluated for the treatment of ROS1-positive NSCLC.
Lead Product(s): Taletrectinib,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Sagard Healthcare Partners
Deal Size: $250.0 million Upfront Cash: Undisclosed
Deal Type: Financing March 03, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Taletrectinib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Sagard Healthcare Partners
Deal Size : $250.0 million
Deal Type : Financing
Nuvation Bio Secures Up to $250M Non-Dilutive Financing from Sagard
Details : The financing is intended to support the clinical development and commercialization of AB-106 (taletrectinib), in the U.S. Currently, it is being evaluated for the treatment of ROS1-positive NSCLC.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
March 03, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Taletrectinib is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Lung Neoplasms.
Lead Product(s): Taletrectinib,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 24, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Taletrectinib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Taletrectinib is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Lung Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 24, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
AB-106 (taletrectinib adipate) is a next-generation ROS1 TKI, which is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC.
Lead Product(s): Taletrectinib,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 03, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Taletrectinib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Nuvation Launches Expanded Access for Taletrectinib in ROS1+ NSCLC in the U.S.
Details : AB-106 (taletrectinib adipate) is a next-generation ROS1 TKI, which is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 03, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Dovbleron (taletrectinib) is a next-generation ROS1 TKI, which is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC.
Lead Product(s): Taletrectinib,Inapplicable
Therapeutic Area: Oncology Brand Name: Dovbleron
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 06, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Taletrectinib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Nuvation Gets China NMPA Approval for Taletrectinib in NSCLC
Details : Dovbleron (taletrectinib) is a next-generation ROS1 TKI, which is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC.
Product Name : Dovbleron
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 06, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
AB-106 (taletrectinib) is a next-generation ROS1 TKI, which is being evaluated for the treatment of adult patients with locally advanced or metastatic NSCLC.
Lead Product(s): Taletrectinib,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 23, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Taletrectinib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
U.S. FDA Accepts Priority Review for Taletrectinib in ROS1-positive NSCLC
Details : AB-106 (taletrectinib) is a next-generation ROS1 TKI, which is being evaluated for the treatment of adult patients with locally advanced or metastatic NSCLC.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 23, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Dovbleron (taletrectinib) is a next-generation ROS1 TKI, indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.
Lead Product(s): Taletrectinib,Inapplicable
Therapeutic Area: Oncology Brand Name: Dovbleron
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 20, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Taletrectinib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Innovent Receives Approval of DOVBLERON® (ROS1 Inhibitor) by China’s NMPA
Details : Dovbleron (taletrectinib) is a next-generation ROS1 TKI, indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.
Product Name : Dovbleron
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 20, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
AB-106 (taletrectinib) is a next-generation ROS1 TKI, which is being evaluated for the treatment of adult patients with locally advanced or metastatic NSCLC.
Lead Product(s): Taletrectinib,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 14, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Taletrectinib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Nuvation Bio to Head to FDA with Pooled ROS1-Positive Lung Cancer Data
Details : AB-106 (taletrectinib) is a next-generation ROS1 TKI, which is being evaluated for the treatment of adult patients with locally advanced or metastatic NSCLC.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 14, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Taletrectinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Lead Product(s): Taletrectinib,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: AnHeart Therapeutics
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 21, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Taletrectinib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : AnHeart Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Taletrectinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 21, 2024

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
89
PharmaCompass offers a list of Taletrectinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Taletrectinib manufacturer or Taletrectinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Taletrectinib manufacturer or Taletrectinib supplier.
PharmaCompass also assists you with knowing the Taletrectinib API Price utilized in the formulation of products. Taletrectinib API Price is not always fixed or binding as the Taletrectinib Price is obtained through a variety of data sources. The Taletrectinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Taletrectinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Taletrectinib, including repackagers and relabelers. The FDA regulates Taletrectinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Taletrectinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Taletrectinib supplier is an individual or a company that provides Taletrectinib active pharmaceutical ingredient (API) or Taletrectinib finished formulations upon request. The Taletrectinib suppliers may include Taletrectinib API manufacturers, exporters, distributors and traders.
click here to find a list of Taletrectinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Taletrectinib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Taletrectinib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Taletrectinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Taletrectinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Taletrectinib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Taletrectinib suppliers with NDC on PharmaCompass.
Taletrectinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Taletrectinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Taletrectinib GMP manufacturer or Taletrectinib GMP API supplier for your needs.
A Taletrectinib CoA (Certificate of Analysis) is a formal document that attests to Taletrectinib's compliance with Taletrectinib specifications and serves as a tool for batch-level quality control.
Taletrectinib CoA mostly includes findings from lab analyses of a specific batch. For each Taletrectinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Taletrectinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Taletrectinib EP), Taletrectinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Taletrectinib USP).